NEW YORK, December 19, 2016 /PRNewswire/ --

http://www.Financialbuzz.com - Ever since certain states voted to approve the use of recreational and medical cannabis use, the legalization of the drug has been a controversial topic throughout the nation. According to a 2016 report from ArcView Market Research, recreational marijuana sales more than tripled from 2014 to 2015 as Colorado and Washington's markets matured, reaching $1.2 billion in 2015. California's population is more than three times larger than Colorado and Washington combined. In 2020, ArcView predicts recreational sales will hit $12 billion nationwide and medical sales will top $10 billion. ChineseInvestors.com Inc. (OTC: CIIX), Terra Tech Corporation (OTC: TRTC), MCig Inc. (OTC: MCIG), Medical Marijuana Inc. (OTC: MJNA), Cannabis Science Inc. (OTC: CBIS).

As stated in "The CBD Report", a definitive report for market sizes and high-level analysis of business trends on the cannabidiol industry by The Hemp Business Journal, it is estimated that the cannabidiol market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. This means a 700% growth from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million, plus another $112 million in marijuana-derived CBD products which were sold through dispensaries, bringing a total cannabidiol market to $202 million last year.

ChineseInvestors.com Inc. (OTCQB: CIIX) describes itself as the premier financial information website for Chinese-speaking investors in both the U.S. and China announced recently that, "a well-known Cannabidiol (CBD) health brand engaged in the development, manufacturing, marketing and distribution of consumer products containing CBD, formed a new wholesale agreement that enables CIIX to retail nutritional supplements containing CBD to the Asian market through both online and in-store sales. The CBD company's flagship product is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry. This leading brand has not only built a reputation for product quality, safety and efficacy, but also offers the most diverse and largest supply of hemp-derived CBD oil on hand in the United States.

Warren Wang, founder and CEO of CIIX, commented: "As more and more states in the U.S. legalize the use of either medical or recreational cannabis, CBD supplements have become a hot spot in the health products market. ChineseInvestors.com is very pleased to enter into a new wholesale agreement with a well-known manufacturer of the top-selling brand of CBD Oil. Through this mutually beneficial partnership, we can positively open the Chinese market in the U.S. and the markets in Asia for CBD products, and continue exploring investment opportunities that further expand our business in the cannabis industry."

Mr. Wang further remarked: "According to The CBD Report published by The Hemp Business Journal, Cannabidiol is one of the fastest growing market categories in the U.S. hemp and legal marijuana industries with a compound annual growth rate of 59%. In 2015, the CBD industry grew from a nearly invisible market a few years ago to $202 million in consumer sales, and it is further expected to grow to $2.1 billion in consumer sales by 2020. Because the Asian market has a prospective consumer base of 4.4 billion people, we are confident that our first step to partner with the leading manufacturer of CBD oil in the world today could have potentially towering profit opportunities."

Terra Tech Corporation (OTCQX: TRTC), is a cannabis-focused agriculture company. The Company operates through two segments: Hydroponic Produce and Cannabis Products. The Company, through its subsidiary, GrowOp Technology Ltd., is engaged in the design, marketing and sale of hydroponic equipment. It is also a retail seller of locally grown hydroponic produce, herbs, and floral products through its subsidiary, Edible Garden Corporation. It plans to operate medical marijuana cultivation, production and dispensary facilities in Nevada through its subsidiaries, MediFarm (3 segments). Through its subsidiary, IVXX Inc., it produces and sells a line of cannabis flowers and cigarettes, among others. The hydroponic produce segment consists of Edible Garden's business and operations.

Diversified company servicing the legal cannabis, hemp, and cannabidiol markets, MCig Inc. (OTCQB: MCIG) has recently released its quarterly financial results. Highlights from the financial results include the company's assets having increased by 300 percent during the fiscal year, gross profit increased by 118% for the quarter and 29% for the six month period ending October 31, 2016 as compared to the same periods in 2015, each reporting operational segment was profitable, and has gained over $200,000 in excess working capital for the fiscal year. "MCIG's rapid business growth & development has necessitated our need to effectively communicate with our shareholder base. We understand the importance of sharing recent events with our shareholders to ensure they have a thorough understanding of our vision and the growth opportunities we have positioned ourselves & shareholders for.," stated MCIG Chief Executive Officer, Paul Rosenberg.

Medical Marijuana Inc. (OTC: MJNA) investment company AXIM® Biotechnologies Inc., receives approval from medical ethical committee of Wageningen University to begin trial for its cannabidiol product, CanChew Plus® chewing gum, for patients suffering from irritable bowel syndrome. "We congratulate AXIM on yet another step forward toward full clinical trials on cannabis-based treatments," said Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana Inc. "With the global treatment market for irritable bowel syndrome estimated to grow in value to $1.5 billion by 2023, cannabis-based products like CanChew Plus® can provide viable solutions for patients suffering from some of the most common of functional gastrointestinal disorders."

Medical marijuana research and development company, Cannabis Science Inc. (OTC: CBIS) works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chinesinvestors.com inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a

particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: [email protected] , +1-877-601-187

Url: FinancialBuzz.com



SOURCE FinancialBuzz.com